ReviewCureus2025
Metabolic Dysregulation and Female Infertility: A Systematic Review of Hormonal and Reproductive Outcomes From Recent Clinical Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Redefining success in assisted reproductive technologies: the Embryo-Maternal-Offspring Continuum Framework.Journal of assisted reproduction and genetics · 2026Review
- Influence of metabolic syndrome on infertility: A review.Metabolism open · 2026Review
- Comparison of glucolipid metabolic profile, thyroid hormone levels, and reproductive endocrine function in polycystic ovary syndrome patients with/without metabolic syndrome.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review explores the influence of metabolic and immunological interventions on hormonal and fertility outcomes in infertile women with metabolic disorders such as polycystic ovary syndrome (PCOS), insulin resistance, obesity, and metabolic syndrome. The review synthesizes findings from rigorously selected randomized and crossover trials published between 2015 and 2024, focusing on interventional approaches aimed at improving reproductive and endocrine parameters. Studies were screened and assessed using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and relevant outcomes included ovulation, oocyte quality, pregnancy rates, and changes in hormonal markers, such as insulin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol. The analysis reveals that metabolic dysregulation significantly alters reproductive outcomes and that targeted interventions, ranging from pharmacological agents and dietary modifications to experimentally induced metabolic states, can have measurable effects on hormonal profiles and fertility. While some interventions demonstrated clear improvements in ovulatory and metabolic markers, others primarily highlighted associations rather than causality. Despite variations in sample sizes and methodological designs, the review underscores the need for integrated therapeutic strategies addressing both metabolic and hormonal dysfunction in this population. The findings support a multifaceted approach to managing infertility in women with metabolic disturbances, emphasizing the potential for tailored interventions to optimize both endocrine and reproductive health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.